ESPRIT (Enhanced Suppression of the Platelet IIb/ IIIa Receptor with eptifibatide Therapy – Засилено подтискане на тромбоцитния рецептор IIb/ IIIa при лечение с ептифибатид) е двойно- сляпо,
ESPRIT (Enhanced Suppression of the Platelet IIb/ IIIa Receptor with eptifibatide Therapy) was a double- blind, randomised, placebo-controlled trial (n= 2,064) for nonurgent PCI with intracoronary stenting.